# CagriSema Dose: Lower Doses Lost About 21% in REDEFINE 9

Source: https://www.dietglp.com/blog/cagrisema-dose/
Published: 2026-11-15
Keywords: cagrisema dose, cagrisema doses, cagrisema dosage chart, cagrisema dosing chart, cagrisema dosage, cagrisema dose for weight loss, cagrisema dose escalation, cagrisema dosing schedule, cagrisema highest dose, cagrisema max dose, cagrisema starting dose, cagrisema fixed dose combination, cagrisema lower dose, redefine 9, redefine 9 cagrisema

**TL;DR:** CagriSema dose is written as two numbers because the shot holds two drugs: cagrilintide and semaglutide. On November 14, 2026, Novo Nordisk reported that two lower doses, 1.0 mg/1.0 mg and 1.7 mg/1.7 mg, led to about 21% average weight loss at 68 weeks in the REDEFINE 9 trial, versus 2% on placebo. CagriSema is not FDA approved, so there is no official dosage chart yet; the FDA is reviewing only the 2.4 mg/2.4 mg dose. On any dose of any GLP-1, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps you keep muscle with one protein target and one 20-minute workout a day.

What is the CagriSema dose, and does a lower dose still work? **CagriSema has no approved dose yet, but trials have now tested three: 1.0 mg/1.0 mg, 1.7 mg/1.7 mg and 2.4 mg/2.4 mg, once a week.** On November 14, 2026, Novo Nordisk shared the first phase 3 results for the two lower doses. In the REDEFINE 9 trial, both led to about 21% average weight loss at 68 weeks. Placebo was 2%. The results were presented at ObesityWeek 2026 and published the same day in The Lancet Diabetes & Endocrinology.

## What do the two numbers in a CagriSema dose mean?

CagriSema is one weekly shot with two drugs in it. Novo calls it a fixed-dose combination.

- **The first number is cagrilintide.** It copies amylin, a fullness hormone your pancreas makes.
- **The second number is semaglutide.** It is the GLP-1 drug in Wegovy and Ozempic.

So "CagriSema 1.0 mg/1.0 mg" means 1.0 mg of each drug in the same injection. In every dose tested so far, the two numbers match. New to this drug? Start with our main [CagriSema guide](/blog/cagrisema/).

## CagriSema dosage chart: every dose tested in phase 3

There is no official CagriSema dosage chart, because there is no FDA label. This table shows the weekly maintenance doses used in the big trials. It is a record of research, not a dosing guide.

| Weekly dose (cagrilintide/semaglutide) | Trial | Who was in it | Length | Average weight loss |
|---|---|---|---|---|
| 1.0 mg/1.0 mg | REDEFINE 9 | 309 adults with obesity or overweight, no diabetes | 68 weeks | 21.0% (placebo 2.0%) |
| 1.7 mg/1.7 mg | REDEFINE 9 | Same trial | 68 weeks | 20.7% (placebo 2.0%) |
| 2.4 mg/2.4 mg | REDEFINE 1 | 3,417 adults with obesity or overweight, no diabetes | 68 weeks | 22.7% (placebo 2.3%) |
| 1.0 mg/1.0 mg | REIMAGINE 5 | 1,023 adults with type 2 diabetes and obesity | 60 weeks | 12.4% (tirzepatide 5 mg: 9.1%) |

The first three rows use the "if everyone stayed on treatment" numbers. People with type 2 diabetes usually lose less weight on these drugs, which is why the last row is lower.

Do not rank the doses from this table. These are separate trials with different people. Novo also says REDEFINE 9 was not powered to detect differences between its two doses. In plain words, the trial cannot tell you that 1.0 mg beats 1.7 mg, even though its number is a hair higher.

## REDEFINE 9 results: what the lower doses did

REDEFINE 9 enrolled 309 adults with a BMI of 30 or more, or 27 or more with a weight-related health problem. None had diabetes. Average starting weight was 109.5 kg, about 241 pounds. Everyone also got lifestyle support.

| At week 68 (if everyone stayed on treatment) | 1.7 mg/1.7 mg | 1.0 mg/1.0 mg | Placebo |
|---|---|---|---|
| Average weight loss | 20.7% | 21.0% | 2.0% |
| Lost 5% or more | 95.1% | 96.3% | 33.4% |
| Lost 10% or more | 87.3% | 86.0% | 13.6% |
| Lost 15% or more | 70.5% | 70.7% | 5.8% |
| Lost 20% or more | 51.3% | 48.3% | 2.7% |
| Waist size change | down 17.2 cm | down 17.5 cm | down 3.6 cm |

Trials also report a stricter number that counts everyone, including people who stopped the drug. On that count, average loss was 19.4% with 1.7 mg/1.7 mg, 18.6% with 1.0 mg/1.0 mg and 4.6% with placebo.

For scale, 21% of 241 pounds is about 50 pounds. About half of the people on either dose lost a fifth of their body weight or more.

## Why would anyone want a lower CagriSema dose?

Because not everyone reaches the top dose. In REDEFINE 1, doctors could keep a person on a lower dose if that suited them better. Novo reported that only 57.3% of people on CagriSema were on the highest dose at week 68.

REDEFINE 9 is the first phase 3 trial to test lower doses on purpose, each against its own placebo. Lead author Dr. Sean Wharton of the University of Toronto said the findings could inform practice, where dosing is often adjusted to the person.

A low dose has also been tested against a rival. In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg beat tirzepatide 5 mg on weight loss in people with type 2 diabetes. Full-dose CagriSema did not beat tirzepatide 15 mg. Both trials are explained in our [CagriSema vs tirzepatide guide](/blog/cagrisema-vs-tirzepatide/).

## CagriSema dose escalation and starting dose

In trials, nobody starts at the target dose. The dose is raised in steps so the stomach can adjust. The public trial registry gives the length of that ramp:

| Target dose | Escalation period in the trial |
|---|---|
| The two lower doses (REDEFINE 9) | 8 weeks for one, 12 weeks for the other |
| 2.4 mg/2.4 mg (REDEFINE 1) | 16 weeks |

Novo has not published an approved starting dose or step-by-step schedule, and we will not guess at one. If CagriSema is approved, the label will set the schedule and your prescriber will follow it. For drugs that already have labels, see our [semaglutide dosage chart](/blog/semaglutide-dosage-chart/) and [Zepbound dosage chart](/blog/zepbound-dosage-chart/).

## Side effects at the lower doses

Novo says safety at both doses matched earlier CagriSema trials. The most common side effects were stomach related and mild to moderate. The share of people who quit because of side effects was small:

| Stopped for side effects | Share |
|---|---|
| CagriSema 1.7 mg/1.7 mg | 2.9% |
| CagriSema 1.0 mg/1.0 mg | 4.9% |
| Placebo | 4.9% |

The release does not give nausea or vomiting rates for REDEFINE 9. In REDEFINE 1, at the 2.4 mg/2.4 mg dose, 79.6% of people had a stomach side effect versus 39.9% on placebo. Whether lower doses are gentler is a fair question, but this small trial cannot settle it. Our guide to [managing nausea on GLP-1 medications](/blog/managing-nausea-on-ozempic/) covers what helps on today's drugs.

## A 21% loss on a "low" dose still puts muscle at risk

The dose may be lower. The weight loss is not small. When a fifth of your body weight comes off, some of it can be muscle unless you work to keep it. That holds for every drug in this class.

Two habits do most of the protecting: enough protein each day and strength training a few times a week. Our [protein target guide](/blog/protein-target-on-glp1/) shows how to find your number. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) turns it into a simple daily plan: one protein target, one 20-minute workout and one Shape Score, so you can see whether you are losing fat and keeping muscle.

## Which CagriSema dose is the FDA reviewing?

Only one. Novo filed its application in December 2025 for **CagriSema 2.4 mg/2.4 mg** for weight management, and says it expects a decision in the fourth quarter of 2026. The release does not say the lower doses have been filed.

That leaves a few things unknown today:

- Which doses would be sold if the FDA says yes.
- What the official starting dose and schedule would be.
- The price, and what insurance would cover.

Until there is a label, CagriSema is only available in clinical trials. Vials sold online as "CagriSema" or a "cagri-sema blend" are not approved medicines, and dosing calculators made for them are not based on any label.

## The bottom line

CagriSema's lower doses work. In REDEFINE 9, 1.0 mg/1.0 mg and 1.7 mg/1.7 mg each led to about 21% weight loss in 68 weeks, close to what the 2.4 mg/2.4 mg dose did in its own trial. There is still no approved dose, no official dosage chart and no FDA decision. If approval comes, the dose is a choice for you and your prescriber. The muscle part is yours either way. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) keeps it simple with one protein target, one 20-minute workout and one Shape Score a day.

## Sources

- [Novo Nordisk, November 14, 2026: CagriSema demonstrated about 21% average weight loss with lower doses in the REDEFINE 9 trial (PR Newswire)](https://www.prnewswire.com/news-releases/novos-investigational-cagrisema-a-glp-1-and-amylin-analog-demonstrated-21-average-weight-loss-with-lower-doses-in-the-redefine-9-trial-presented-at-obesityweek-2026-and-published-in-the-lancet-diabetes--endocrinology-302939556.html)
- [ClinicalTrials.gov NCT06388187: REDEFINE 9, CagriSema 1.0 mg/1.0 mg and 1.7 mg/1.7 mg](https://clinicaltrials.gov/study/NCT06388187)
- [ClinicalTrials.gov NCT05567796: REDEFINE 1](https://clinicaltrials.gov/study/NCT05567796)
- [Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). NEJM, 2025 (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40544433/)
- [Novo Nordisk, December 18, 2025: Novo Nordisk files for FDA approval of CagriSema (PR Newswire)](https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html)


## Frequently asked questions

**Q: What is the dose of CagriSema?**

A: CagriSema has no approved dose yet. Trials have tested three once-weekly maintenance doses: 1.0 mg/1.0 mg, 1.7 mg/1.7 mg and 2.4 mg/2.4 mg. The first number is cagrilintide and the second is semaglutide. Novo Nordisk asked the FDA to approve the 2.4 mg/2.4 mg dose for weight management.

**Q: Is there a CagriSema dosage chart?**

A: Not an official one. A real dosage chart comes from an FDA label, and CagriSema does not have a label yet. What exists today is a list of the doses used in clinical trials. Any chart online that gives week-by-week CagriSema doses is not based on an approved label.

**Q: What is the highest dose of CagriSema?**

A: The highest dose studied in the phase 3 REDEFINE program is 2.4 mg of cagrilintide plus 2.4 mg of semaglutide, once a week. That is the dose Novo Nordisk filed with the FDA in December 2025.

**Q: Do lower doses of CagriSema work?**

A: In the REDEFINE 9 trial they did. People on 1.0 mg/1.0 mg lost 21.0% of their weight on average and people on 1.7 mg/1.7 mg lost 20.7% at 68 weeks, if everyone stayed on treatment. Placebo was 2.0%. The trial was not built to tell the two doses apart.

**Q: How is the CagriSema dose escalated?**

A: In trials, the dose was raised in steps before it reached the target. The trial registry lists escalation periods of 8 and 12 weeks for the two lower doses in REDEFINE 9, and 16 weeks for the 2.4 mg/2.4 mg dose in REDEFINE 1. An official schedule will only exist if the FDA approves a label.

**Q: Is CagriSema FDA approved?**

A: No. As of November 15, 2026, CagriSema is not approved in the United States. Novo Nordisk filed for the 2.4 mg/2.4 mg dose in December 2025 and says it expects a decision in the fourth quarter of 2026.

**Q: Can I buy a CagriSema blend and dose it myself?**

A: No approved CagriSema product is sold anywhere. Vials sold online as CagriSema or cagri-sema blends have not been reviewed by the FDA for safety, purity or dose. Dosing calculators for them are not based on a label. Talk to your prescriber about approved options.

